Janux reports Q3 net loss $28.1M; cash $658M; JANX007 update expected by year-end

Janux Therapeutics, Inc.

2024-Q3 EPS reported -$0.93 revenue$10,588,000

Cash and short-term investments $658.0M at Sept 30, 2024 vs $344.0M at Dec 31, 2023.
Net loss $28.1M for Q3 2024 vs $11.6M in Q3 2023; R&D expenses $18.6M vs $11.9M.
G&A expenses $17.7M for Q3 2024 including $9.5M stock-based compensation from equity modifications.
Enrollment continues for JANX007 (PSMA-TRACTr) in mCRPC and JANX008 (EGFR-TRACTr) in solid tumors.
Update on JANX007 data and expansion cohort doses anticipated in 2024; JANX008 update in 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.